Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558289 | 0.86 | BRAF (0.35) | SCN10AALDH1A1GRM1ESR1JAK2 | |
| SCHEMBL10227953 | 0.81 | SCN10A (0.38) | SCN10AALDH1A1GRM1ESR1JAK2 | |
| SCHEMBL30133886 | 0.81 | SCN10A (0.34) | SCN10AALDH1A1JAK2ROCK2PRKCQ | |
| SCHEMBL17157434 | 0.81 | SCN10A (0.34) | SCN10AALDH1A1JAK2ROCK2PRKCQ | |
| SCHEMBL17157388 | 0.81 | AR (0.35) | SCN10AJAK2ROCK2PRKCQPRKCD | |
| SCHEMBL17157437 | 0.81 | AR (0.38) | SCN10AALDH1A1JAK2ROCK2PRKCQ | |
| SCHEMBL2817699 | 0.80 | CYP3A4 (0.45) | SCN10AALDH1A1GRM1ESR1BRAF | |
| SCHEMBL17157322 | 0.78 | CASP1 (0.42) | SCN10AALDH1A1CYP3A4 | |
| SCHEMBL17157402 | 0.78 | ESR1 (0.36) | SCN10AESR1CYP19A1UGT1A4PDE4D | |
| SCHEMBL12866834 | 0.78 | SCN10A (0.36) | SCN10AGRM1ESR1JAK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167300-B2 | Metalloenzyme inhibitor compounds as fungicides | DOW AGROSCIENCES LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-10167300-B2 | Metalloenzyme inhibitor compounds as fungicides | DOW AGROSCIENCES LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180298038-A1 | METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20180290998-A1 | METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2018-10-11 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-9957252-B2 | Metalloenzyme inhibitor compounds as fungicides | DOW AGROSCIENCES LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9944664-B2 | Metalloenzyme inhibitor compounds as fungicides | DOW AGROSCIENCES LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944664-B2 | Metalloenzyme inhibitor compounds as fungicides | DOW AGROSCIENCES LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944664-B2 | Metalloenzyme inhibitor compounds as fungicides | DOW AGROSCIENCES LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170233369-A1 | METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES | DOW AGROSCIENCES LLC | 2017-08-17 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| WO-2010098487-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-2051967-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | AstraZeneca AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | CHRNA1 2286/4885CHRNG 3215/4885CHRNB1 2216/4885 |
| US-10167300-B2 | Metalloenzyme inhibitor compounds as fungicides | GPX1, POR, MGAM | CHRNA1 3434/4885CHRNG 3432/4885CHRNB1 3737/4885 |
| US-20180290998-A1 | METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES | GPX1, POR, MGAM | CHRNA1 3434/4885CHRNG 3432/4885CHRNB1 3737/4885 |
| US-20170233369-A1 | METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES | GPX1, POR, MGAM | CHRNA1 3434/4885CHRNG 3432/4885CHRNB1 3737/4885 |
| US-20180298038-A1 | METALLOENZYME INHIBITOR COMPOUNDS AS FUNGICIDES | GPX1, POR, MGAM | CHRNA1 3434/4885CHRNG 3432/4885CHRNB1 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.